- JP-listed companies
- OncoTherapy Science, Inc.
- Financials
- Operating margin (%)
OncoTherapy Science, Inc. (4564)
Market cap
¥6.4B
P/E ratio
OncoTherapy Science develops cancer treatments using genetic research, including targeted drugs, immunotherapies, and precision medicine testing for personalized cancer care.
| Period End | Operating margin (%) | YoY (%) |
|---|---|---|
| Mar 31, 2025 | -106.4 | -42.09% |
| Mar 31, 2024 | -183.7 | +88.43% |
| Mar 31, 2023 | -97.5 | -45.21% |
| Mar 31, 2022 | -177.9 | -63.88% |
| Mar 31, 2021 | -492.6 | -28.86% |
| Mar 31, 2020 | -692.5 | -34.22% |
| Mar 31, 2019 | -1,052.7 | -25.59% |
| Mar 31, 2018 | -1,414.7 | +34.99% |
| Mar 31, 2017 | -1,048 | -6.17% |
| Mar 31, 2016 | -1,116.8 | +338.18% |
| Mar 31, 2015 | -254.9 |